Nathan Sanicharane has been appointed as new business development manager for the chemicals sector at safety equipment specialist Draeger Safety UK. 
Sanicharane has a Masters degree in Chemistry and has spent four years working in drugs development. He also has nearly five years’ experience in selling chromatography and specialist chemicals.
                    
                
Draeger hires new business development manager
Nathan Sanicharane takes up the role
You may also like
                                                            Regulatory
                                                        
                                
                                                                            
                                                                    
                                
                    Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I
Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation
                                                                    
                                
                            
                        
                                                            Regulatory
                                                        
                                
                                                                            
                                                                    
                                
                    MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
                                                                    
                                
                            
                        
                                                            Regulatory
                                                        
                                
                                                                            
                                                                    
                                
                    NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case
The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach